Aethlon Medical (NASDAQ:AEMD) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMDFree Report) in a report issued on Saturday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright decreased their price objective on Aethlon Medical from $23.00 to $10.00 and set a buy rating for the company in a report on Monday, March 4th.

Check Out Our Latest Stock Analysis on AEMD

Aethlon Medical Price Performance

AEMD opened at $1.46 on Friday. The company has a market capitalization of $3.83 million, a price-to-earnings ratio of -0.29 and a beta of 1.88. The business’s 50-day moving average price is $1.66 and its two-hundred day moving average price is $1.76. Aethlon Medical has a 1 year low of $1.35 and a 1 year high of $7.20.

Aethlon Medical (NASDAQ:AEMDGet Free Report) last announced its quarterly earnings data on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.14). Sell-side analysts anticipate that Aethlon Medical will post -4.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aethlon Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC grew its holdings in Aethlon Medical by 11.6% during the first quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock worth $395,000 after purchasing an additional 28,097 shares during the period. Two Sigma Investments LP bought a new position in Aethlon Medical during the third quarter worth about $32,000. HRT Financial LP bought a new position in Aethlon Medical during the fourth quarter worth about $28,000. Citadel Advisors LLC bought a new position in Aethlon Medical during the third quarter worth about $72,000. Finally, Jane Street Group LLC grew its holdings in Aethlon Medical by 895.7% during the fourth quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 126,160 shares during the period. Institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

(Get Free Report)

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

Featured Articles

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.